A Phase 3 Multi-center Randomized Open-Label Study of Carbavance (Meropenem/PRX7009) Versus Best Available Therapy in Subjects with Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Administered By
Awarded By
Contributors
- Hendershot, Edward Ferguson Principal Investigator
Start/End
- December 15, 2014 - December 14, 2017